Self-measurement of blood glucose (SMBG) by means of glucose test strips is a cornerstone of diabetes management. However, the clinical benefit of SMBG in non-insulin treated patients with type 2 diabetes mellitus (T2DM) is under debate. In Switzerland, these patients are currently reimbursed a maximum of 400 test strips per year by the compulsory health insurance. The aim of this HTA was to evaluate the effectiveness, cost-effectiveness and budget impact of further restricting or eliminating the coverage of test strip in non-insulin treated T2DM, whilst accounting for organisational, legal, ethical and socio-cultural aspects.